Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Capital Expenditures: 2009-2025

Historic Capital Expenditures for China Pharma Holdings (CPHI) over the last 14 years, with Sep 2025 value amounting to $611.

  • China Pharma Holdings' Capital Expenditures rose 106.63% to $611 in Q3 2025 from the same period last year, while for Sep 2025 it was $78,415, marking a year-over-year increase of 34.59%. This contributed to the annual value of $38,411 for FY2024, which is 233.52% up from last year.
  • As of Q3 2025, China Pharma Holdings' Capital Expenditures stood at $611, which was up 1,040.00% from -$65 recorded in Q2 2025.
  • China Pharma Holdings' Capital Expenditures' 5-year high stood at $415,977 during Q3 2021, with a 5-year trough of -$55,964 in Q1 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $611 (2025), whereas its average is $8,968.
  • As far as peak fluctuations go, China Pharma Holdings' Capital Expenditures crashed by 4,123.29% in 2023, and later surged by 331.74% in 2024.
  • Over the past 5 years, China Pharma Holdings' Capital Expenditures (Quarterly) stood at $7,056 in 2021, then crashed by 486.45% to -$27,268 in 2022, then surged by 116.60% to $4,527 in 2023, then skyrocketed by 331.74% to $19,545 in 2024, then spiked by 106.63% to $611 in 2025.
  • Its Capital Expenditures was $611 in Q3 2025, compared to -$65 in Q2 2025 and $58,324 in Q1 2025.